Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
SNYDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 3, 2026 | $2.42 | 2026-05-04 | 2026-05-04 |
| June 12, 2025 | $2.20 | 2025-05-09 | 2025-05-09 |
| June 6, 2024 | $2.04 | 2024-05-09 | 2024-05-10 |
| June 23, 2023 | $1.90 | 2023-05-30 | 2023-05-31 |
| May 31, 2022 | $1.75 | 2022-05-04 | 2022-05-05 |
Dividends Summary
- Consistent Payer: Sanofi American Depositary Shares (Each representing one-half of one ordinary share) has rewarded shareholders with 19 dividend payments over the past 18 years.
- Total Returned Value: Investors who held SNY shares during this period received a total of $34.04 per share in dividend income.
- Latest Payout: The most recent dividend of $2.42/share was paid 45 days ago, on June 3, 2026.
- Yield & Schedule: SNY currently pays dividends yearly with an annual yield of 5.42%.
- Dividend Growth: Since 2008, the dividend payout has grown by 48.8%, from $1.63 to $2.42.
- Growth Streak: SNY has raised its dividend for 5 consecutive payments.
Company News
ResearchAndMarkets.com released a comprehensive report analyzing over 1,859 clinical-stage pharmaceutical and biotechnology partnership deals announced since 2020. The report provides detailed financial terms, deal structures, contract documents, and insights into negotiation dynamics for clinical-stage drug development collaborations, serving as...
The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% ...
Moderna and Recursion Pharmaceuticals represent two distinct approaches to biotech innovation: Moderna leverages proven mRNA technology with diversifying pipeline into oncology and rare diseases, while Recursion uses AI-driven drug discovery. Despite both operating at losses, Moderna is favored for 2026 due to its established revenue base and pro...
Dupilumab (Dupixent) continues strong growth with €10.7 billion in 2023 sales and $4.34 billion in Q2 2025. FDA approval for COPD in September 2024 and expansion to chronic spontaneous urticaria in children unlock new market opportunities. The drug demonstrates clinical superiority over competitors like Xolair, with market projections extending...
Sanofi announced the availability of its aide-mémoire for Q2 2026 results on July 1, 2026, to support financial modeling of quarterly results. The document covers non-comparable items, foreign currency impact, and share count. Full Q2 2026 results will be published on July 30, 2026.
